- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT01483625
Tiotropium (18mcg) in Chronic Obstructive Pulmonary Disease (COPD) Patients With a Respiratory Infection
A 12-week, Randomised, Placebo-controlled, Double-blind, Parallel Group, Multi-center Trial to Assess the Efficacy and Safety of Tiotropium Bromide (18 µg) Delivered Via the HandiHaler® in Patients With Newly Diagnosed and/or Maintenance Treatment naïve Chronic Obstructive Pulmonary Disease (COPD) Experiencing an Acute Respiratory Infection (TICARI 1: Tiotropium In COPD Patients With an Acute Respiratory Infection 1)
Studie Overzicht
Toestand
Conditie
Interventie / Behandeling
Studietype
Inschrijving (Werkelijk)
Fase
- Fase 4
Contacten en locaties
Studie Locaties
-
-
Arizona
-
Tucson, Arizona, Verenigde Staten
- 205.479.01017 Boehringer Ingelheim Investigational Site
-
-
California
-
Riverside, California, Verenigde Staten
- 205.479.01036 Boehringer Ingelheim Investigational Site
-
San Diego, California, Verenigde Staten
- 205.479.01024 Boehringer Ingelheim Investigational Site
-
-
Florida
-
DeLand, Florida, Verenigde Staten
- 205.479.01043 Boehringer Ingelheim Investigational Site
-
St. Petersburg, Florida, Verenigde Staten
- 205.479.01040 Boehringer Ingelheim Investigational Site
-
-
Michigan
-
Chelsea, Michigan, Verenigde Staten
- 205.479.01022 Boehringer Ingelheim Investigational Site
-
-
Mississippi
-
Picayune, Mississippi, Verenigde Staten
- 205.479.01041 Boehringer Ingelheim Investigational Site
-
-
Missouri
-
St. Louis, Missouri, Verenigde Staten
- 205.479.01037 Boehringer Ingelheim Investigational Site
-
-
North Carolina
-
Tabor City, North Carolina, Verenigde Staten
- 205.479.01005 Boehringer Ingelheim Investigational Site
-
Wilmington, North Carolina, Verenigde Staten
- 205.479.01008 Boehringer Ingelheim Investigational Site
-
-
Ohio
-
Cincinnati, Ohio, Verenigde Staten
- 205.479.01003 Boehringer Ingelheim Investigational Site
-
-
Pennsylvania
-
Pittsburgh, Pennsylvania, Verenigde Staten
- 205.479.01002 Boehringer Ingelheim Investigational Site
-
Tipton, Pennsylvania, Verenigde Staten
- 205.479.01044 Boehringer Ingelheim Investigational Site
-
-
South Carolina
-
Charleston, South Carolina, Verenigde Staten
- 205.479.01006 Boehringer Ingelheim Investigational Site
-
Columbia, South Carolina, Verenigde Staten
- 205.479.01001 Boehringer Ingelheim Investigational Site
-
Easley, South Carolina, Verenigde Staten
- 205.479.01007 Boehringer Ingelheim Investigational Site
-
Fort Mill, South Carolina, Verenigde Staten
- 205.479.01026 Boehringer Ingelheim Investigational Site
-
Gaffney, South Carolina, Verenigde Staten
- 205.479.01031 Boehringer Ingelheim Investigational Site
-
Greenville, South Carolina, Verenigde Staten
- 205.479.01012 Boehringer Ingelheim Investigational Site
-
Hodges, South Carolina, Verenigde Staten
- 205.479.01048 Boehringer Ingelheim Investigational Site
-
Spartanburg, South Carolina, Verenigde Staten
- 205.479.01004 Boehringer Ingelheim Investigational Site
-
Union, South Carolina, Verenigde Staten
- 205.479.01019 Boehringer Ingelheim Investigational Site
-
-
South Dakota
-
Rapid City, South Dakota, Verenigde Staten
- 205.479.01039 Boehringer Ingelheim Investigational Site
-
-
Tennessee
-
Chattanooga, Tennessee, Verenigde Staten
- 205.479.01033 Boehringer Ingelheim Investigational Site
-
-
Texas
-
Killeen, Texas, Verenigde Staten
- 205.479.01028 Boehringer Ingelheim Investigational Site
-
-
Virginia
-
Ettrick, Virginia, Verenigde Staten
- 205.479.01038 Boehringer Ingelheim Investigational Site
-
Norfolk, Virginia, Verenigde Staten
- 205.479.01047 Boehringer Ingelheim Investigational Site
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Beschrijving
Inclusion criteria:
- All patients must sign an informed consent consistent with International Conference on Harmonization - Good Clinical Practice (ICH-GCP) guidelines prior to participation in the trial and conducting any study procedures.
- Male or female patients 40 years of age or older.
- Ability to independently read and understand English and/or Spanish.
- Any self-reported history of smoking (e.g. = 100 cigarettes (~5 packs) during life-time).
- Acute respiratory symptoms for up to 7 days
- All patients must have a diagnosis of COPD, and must have an airway obstruction with a post-bronchodilator (Forced Expiratory Volume in 1 second (FEV1)/Forced Vital Capacity (FVC)) <0.7. The diagnosis of COPD can be made at Visit 1.
- The clinical assessment of the enrolled patient in the judgement of the investigator supports the introduction of COPD maintenance therapy.
- Patients must be able to inhale medication in a competent manner from the HandiHaler® device and from a metered dose inhaler (MDI)
Exclusion criteria:
Therapy with any long-acting bronchodilator, short-acting anticholinergic, inhaled corticosteroid or regular maintenance use (>14 consecutive days) of systemic corticosteroid (the latter for respiratory indications) during the previous 6 months (short course of systemic corticosteroid for up to 14 days for respiratory indications allowed); in case of use of systemic corticosteroid medication for other than respiratory conditions, then exclusion of unstable doses (i.e., less than six weeks on stable dose) or at doses in excess of the equivalent of 10 mg prednisolone-equivalent per day. In addition, daily use of short-acting beta2-agonist for more than a week prior to Visit 0 not allowed.
The following exclusion criteria apply at Visit 1:
- Significant diseases other than COPD. A significant disease is defined as a disease or condition which, in the opinion of the investigator, may put the patient at risk because of participation in the study or may influence the patient¿s ability to participate in the study.
- A recent history (i.e., six months or less) of myocardial infarction. Patients being stable with a history of cardiac stents prior to six month are permitted.
- Any unstable or life-threatening cardiac arrhythmia requiring intervention or change in drug therapy during the last year.
- Hospitalisation for cardiac failure (New York Heart Association (NYHA) Class III or IV) during the past year.
- Any significant or new ECG findings at V1 as judged by the investigator, including, but not limited to signs of ischemia, arrhythmia, heart failure, or the report of chest pain.
- Known active tuberculosis.
- Current asthma (patient treated for asthma in the last 2 years), cystic fibrosis, clinical diagnosis of bronchiectasis, interstitial lung disease, or pulmonary thromboembolic disease.
- A history of thoracotomy with pulmonary resection. Patients with a history of thoracotomy for other reasons should be evaluated as per exclusion criterion no. 2.
- Malignancy for which the patient has undergone resection, radiation, chemotherapy or biological treatments within the last year or is currently on active radiation therapy, chemotherapy or biological treatment. Patients with treated basal cell carcinoma are allowed.
- At visit 0 or 1, a severe respiratory infection, e.g. pneumonia (as suspected by investigator), any condition or exacerbation requiring ER visit or hospitalization, need for oxygen treatment.
- Known hypersensitivity to anticholinergic drugs, lactose, or any other components of the HandiHaler® or MDI inhalation solution delivery system.
- Treatment with any restricted pulmonary medication
- Requirement of supplemental oxygen therapy for = 24 hours during the previous 6 months.
- Known moderate to severe renal impairment.
- Known narrow angle glaucoma.
- Significant symptomatic prostatic hyperplasia or bladder-neck obstruction. Patients whose symptoms are controlled on treatment may be included.
- Pregnant or nursing women or women of childbearing potential not using a medically approved means of contraception (i.e., oral contraceptives, intrauterine devices, diaphragm or subdermal implants e.g., Norplant®) for at least three months prior to and for the duration of the trial.
- Significant alcohol or drug abuse within the past 12 months.
- Actively participating in a pulmonary rehabilitation program.
- Previously randomized in this study or currently participating in another interventional study.
- Visual impairment that as judged by the investigator does not allow the patient to independently read and complete the questionnaires and electronic diary (eDiary).
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Behandeling
- Toewijzing: Gerandomiseerd
- Interventioneel model: Parallelle opdracht
- Masker: Dubbele
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
---|---|
Placebo-vergelijker: Placebo
placebo
|
placebo
|
Experimenteel: tiotropium 18mcg
active
|
18mcg
|
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
---|---|---|
Trough FEV1 After 12 Weeks on Study Drug
Tijdsspanne: 12 weeks
|
The primary endpoint was trough forced expiratory volume in 1 second (FEV1) after 12 weeks on study drug.
Trough forced expiratory volume in 1 second (FEV1)was defined as the FEV1 measurement prior to the next dosing of study drug and approximately 24 hours after the last inhalation of study drug.
|
12 weeks
|
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
---|---|---|
Time to Recovery From Acute Respiratory Symptoms
Tijdsspanne: 12 weeks
|
Time to recovery was assessed with the EXACT-PRO questionnaire tool. The EXACT-PRO was designed to collect data to quantify frequency, severity, and duration of exacerbations in patients with COPD including the onset of and the recovery from COPD exacerbations. The EXACT-PRO is a 14-item questionnaire. Each attribute or item was assessed on a five- or six-point ordinal scale and summed to yield a total score that was converted to a 0-100 scale, with higher scores indicating a more severe health state or exacerbation. The EXACT-PRO was answered by the patients on a daily basis in the evening. |
12 weeks
|
Trough FVC (in Litres) at 12 Weeks
Tijdsspanne: 12 weeks
|
The trough Forced Vital Capacity (FVC) was defined as the FVC measurement prior to the next dosing of study drug and approximately 24 hours after the last inhalation of study drug.
|
12 weeks
|
Responder Status at Week 4 Clinic Visit
Tijdsspanne: 4 weeks
|
Responder status was determined at each clinic visit. The number and percentage of subjects in each of the following 3 classes were presented:
|
4 weeks
|
Responder Status at Week 12 Clinic Visit
Tijdsspanne: 12 weeks
|
Responder status was determined at each clinic visit. The number and percentage of subjects in each of the following 3 classes were presented:
|
12 weeks
|
Weekly Rescue Medication Use Over the 12 Weeks of Study
Tijdsspanne: 12 weeks
|
Daily rescue albuterol use was recorded in the diary in response to the following question: How many puffs of rescue medication did you use during the last 24 hours?
The weekly rescue medication use was derived by summing the daily uses over the 12 weeks and dividing this total by 12 weeks.
|
12 weeks
|
Medewerkers en onderzoekers
Sponsor
Publicaties en nuttige links
Nuttige links
Studie record data
Bestudeer belangrijke data
Studie start
Primaire voltooiing (Werkelijk)
Studie voltooiing (Werkelijk)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Schatting)
Updates van studierecords
Laatste update geplaatst (Schatting)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Aanvullende relevante MeSH-voorwaarden
- Infecties
- Ziekten van de luchtwegen
- Longziekten
- Longziekten, obstructief
- Longziekte, chronisch obstructief
- Luchtweginfecties
- Fysiologische effecten van medicijnen
- Neurotransmitter agenten
- Moleculaire mechanismen van farmacologische werking
- Parasympathicolytica
- Autonome agenten
- Agenten van het perifere zenuwstelsel
- Cholinerge antagonisten
- Cholinerge middelen
- Bronchusverwijdende middelen
- Anti-astmatische middelen
- Agenten van het ademhalingssysteem
- Tiotropiumbromide
Andere studie-ID-nummers
- 205.479
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .
Klinische onderzoeken op Placebo
-
SamA Pharmaceutical Co., LtdOnbekendAcute bronchitis | Acute bovenste luchtweginfectieKorea, republiek van
-
National Institute on Drug Abuse (NIDA)VoltooidCannabisgebruikVerenigde Staten
-
AstraZenecaParexel; Spandauer Damm 130; 14050; Berlin, GermanyVoltooidMannelijke proefpersonen met diabetes type II (T2DM)Duitsland
-
Heptares Therapeutics LimitedVoltooidFarmacokinetiek | Veiligheid problemenVerenigd Koninkrijk
-
Texas A&M UniversityNutraboltVoltooidGlucose and Insulin Response
-
Soroka University Medical CenterVoltooid
-
Regado Biosciences, Inc.VoltooidGezonde vrijwilligerVerenigde Staten
-
Longeveron Inc.BeëindigdHypoplastisch linkerhartsyndroomVerenigde Staten
-
ItalfarmacoVoltooidBecker spierdystrofieNederland, Italië